目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Distribution Channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class Outlook
2.2.2. Distribution Channel Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights

Chapter 3. Hyperkalemia Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Hyperkalemia drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Hyperkalemia Drugs Market: Pipeline Analysis

Chapter 4. Hyperkalemia Drugs Market: Drug Class Estimates & Trend Analysis
4.1. Drug Class Segment Dashboard
4.2. Hyperkalemia Drugs Market: Drug Class Movement Analysis
4.3. Global Hyperkalemia Drugs Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
4.4. Novel Oral Potassium Binders
4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Traditional Cation-Exchange Resins
4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Others
4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hyperkalemia Drugs Market: Distribution Channel Estimates & Trend Analysis
5.1. Distribution Channel Segment Dashboard
5.2. Hyperkalemia Drugs Market: Distribution Channel Movement Analysis
5.3. Global Hyperkalemia Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
5.4. Hospital Pharmacies
5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Retail Pharmacies
5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Online Pharmacies
5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hyperkalemia Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2033
6.3. Hyperkalemia Drugs Market by Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Canada
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Mexico
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
6.5.2. Germany
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
6.5.3. France
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
6.5.4. Italy
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
6.5.5. Spain
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
6.5.6. Norway
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
6.5.7. Sweden
6.5.7.1. Key country dynamics
6.5.7.2. Regulatory framework/ reimbursement structure
6.5.7.3. Competitive scenario
6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
6.5.8. Denmark
6.5.8.1. Key country dynamics
6.5.8.2. Regulatory framework/ reimbursement structure
6.5.8.3. Competitive scenario
6.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
6.6.2. China
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
6.6.3. India
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
6.6.4. Australia
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
6.6.5. South Korea
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
6.6.6. Thailand
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
6.7.2. Argentina
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
6.8.3. UAE
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key country dynamics
6.8.4.2. Regulatory framework/ reimbursement structure
6.8.4.3. Competitive scenario
6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. AstraZeneca plc
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. CSL Vifor (Vifor Pharma AG)
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Sanofi
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Kowa Company, Ltd.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. KVK-Tech, Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Fresenius Kabi AG
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Novo Nordisk A/S
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives

List of Tables
Table 1 List of abbreviations
Table 2 Global hyperkalemia drugs market, by region, 2021 - 2033 (USD Million)
Table 3 Global hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 4 Global hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 5 North America hyperkalemia drugs market, by country, 2021 - 2033 (USD Million)
Table 6 North America hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 7 North America hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 8 U.S. hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 9 U.S. hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 10 Canada hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 11 Canada hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 12 Mexico hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 13 Mexico hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 14 Europe hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
Table 15 Europe hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 16 Europe hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 17 Germany hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 18 Germany hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 19 UK hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 20 UK hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 21 France hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 22 France hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 23 Italy hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 24 Italy hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 25 Spain hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 26 Spain hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 27 Denmark hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 28 Denmark hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 29 Sweden hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 30 Sweden hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 31 Norway hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 32 Norway hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 33 Asia Pacific hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
Table 34 Asia Pacific hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 35 Asia Pacific hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 36 China hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 37 China hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 38 Japan hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 39 Japan hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 40 India hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 41 India hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 42 South Korea hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 43 South Korea hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 44 Australia hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 45 Australia hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 46 Thailand hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 47 Thailand hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 48 Latin America hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
Table 49 Latin America hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 50 Latin America hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 51 Brazil hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 52 Brazil hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 53 Argentina hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 54 Argentina hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 55 Middle East & Africa hyperkalemia drugs market, by Country, 2021 - 2033 (USD Million)
Table 56 Middle East & Africa hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 57 Middle East & Africa hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 58 South Africa hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 59 South Korea hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 60 Saudi Arabia hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 61 Saudi Arabia hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 62 UAE hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 63 UAE hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)
Table 64 Kuwait hyperkalemia drugs market, by drug class, 2021 - 2033 (USD Million)
Table 65 Kuwait hyperkalemia drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Market snapshot
Fig. 8 Hyperkalemia drugs market segmentation
Fig. 9 Market Snapshot
Fig. 10 Therapeutic approach and disease outlook (USD Million)
Fig. 11 Competitive landscape
Fig. 12 Hyperkalemia drugs market dynamics
Fig. 13 Hyperkalemia drugs market: Porter’s five forces analysis
Fig. 14 Hyperkalemia drugs market: PESTLE analysis
Fig. 15 Drug class market, 2021 - 2033 (USD Million)
Fig. 16 Novel oral potassium binders market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 17 Traditional Cation-Exchange Resins market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 18 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 19 Distribution channel market, 2021 - 2033 (USD Million)
Fig. 20 Hospital Pharmacies market estimates and forecast, 2021 - 2033
Fig. 21 Retail Pharmacies market estimates and forecast, 2021 - 2033
Fig. 22 Online Pharmacies market estimates and forecast, 2021 - 2033
Fig. 23 Hyperkalemia drugs market revenue, by region
Fig. 24 Regional marketplace: Key takeaways
Fig. 25 North America hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 26 U.S. country dynamics
Fig. 27 U.S. hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 28 Canada country dynamics
Fig. 29 Canada hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 30 Mexico country dynamics
Fig. 31 Mexico hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 32 Europe hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 33 UK country dynamics
Fig. 34 UK hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 35 Germany country dynamics
Fig. 36 Germany hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 37 France country dynamics
Fig. 38 France hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 39 Italy country dynamics
Fig. 40 Italy hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 41 Spain country dynamics
Fig. 42 Spain hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 43 Norway country dynamics
Fig. 44 Norway hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 45 Sweden country dynamics
Fig. 46 Sweden hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 47 Denmark country dynamics
Fig. 48 Denmark hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 49 Asia Pacific hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 50 Japan country dynamics
Fig. 51 Japan hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 52 China country dynamics
Fig. 53 China hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 54 India country dynamics
Fig. 55 India hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 56 Australia country dynamics
Fig. 57 Australia hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 58 South Korea country dynamics
Fig. 59 South Korea hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 60 Thailand country dynamics
Fig. 61 Thailand hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 62 Latin America hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 63 Brazil country dynamics
Fig. 64 Brazil hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 65 Argentina country dynamics
Fig. 66 Argentina hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 67 MEA hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 68 South Africa country dynamics
Fig. 69 South Africa hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 70 Saudi Arabia country dynamics
Fig. 71 Saudi Arabia hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 72 UAE country dynamics
Fig. 73 UAE hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 74 Kuwait country dynamics
Fig. 75 Kuwait hyperkalemia drugs market, 2021 - 2033 (USD Million)
Fig. 76 Company categorization
Fig. 77 Company market position analysis
Fig. 78 Strategic framework